Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atirmociclib - Pfizer

Drug Profile

Atirmociclib - Pfizer

Alternative Names: PF-07220060

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Amines; Antineoplastics; Benzimidazoles; Cyclic ethers; Halogenated hydrocarbons; Propanols; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer
  • Phase II Breast cancer; Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 07 Jan 2025 Pfizer plans phase-III FourLight-3 trial for HER2-negative bBreast cancer (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in USA (PO, Tablet) in February 2025 (NCT06760637),
  • 06 Jan 2025 Phase-III clinical trials in HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in Japan and USA (PO) (EudraCT2024-512925-95-00) (NCT06760637)
  • 24 Dec 2024 Chemical structure information added.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top